More recently, Xu et al. [35] showed that mutated deficient CDKN2A in RCC patients is associated with sarcomatoid differentiation, tumor progression, poor prognosis and primary resistance to Sunitinib, and potential favorable responses to ICIs. This evidence concerns the gene CDKN2A and neoplasm.